Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo

@article{Millan1998SerotoninR,
  title={Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo},
  author={Mark J Millan and Anne Dekeyne and Alain P. Gobert},
  journal={Neuropharmacology},
  year={1998},
  volume={37},
  pages={953-955}
}
In-vivo assessment of 5-HT and 5-HT antagonistic 2A 2C properties of newer antipsychotics
TLDR
The effects of serotonin 5-HT receptor ligands on the MK 212 6-chloro-2 1-piperazinyl pyrazine discriminative stimulus and quipazine-induced head twitches were studied in rats, suggesting that the MK212 discriminATIVE stimulus is mediated by 5- HT receptors, while quipazines-in2C duced head twitching are mediated primarily by5-HT receptors.
Differential effects of 5-HT2C receptor ligands on place conditioning and locomotor activity in rats.
...
...

References

SHOWING 1-7 OF 7 REFERENCES
S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
TLDR
S 15535 is a selective ligand of cloned, h5-HT1A receptors, and its agonist actions at 5- HT1A autoreceptors underlie its ability to decrease extracellular levels of 5-HT in the FCX, and likely contribute to the increase in extrace cellular levels of DA and NAD evoked by S 15535 in this structure.
Dopamine, the prefrontal cortex and schizophrenia
TLDR
Parts of the anatomy, physiology and pharmacology of the mesencephalic-frontal cortical dopamine system as they may relate to schizophrenia are described, and evidence for altered dopaminergic neurotransmission in the frontal cortex of schizophrenic patients is presented.
Novel agonists of 5HT2C receptors. Synthesis and biological evaluation of substituted 2-(indol-1-yl)-1-methylethylamines and 2-(indeno[1,2-b]pyrrol-1-yl)-1-methylethylamines. Improved therapeutics for obsessive compulsive disorder.
TLDR
Compounds were functionally characterized both in vitro and in vivo as 5HT2C receptor agonists and exhibited anticompulsive activity in an animal model of obsessive compulsive disorder.